Impact of different vehicles for laser-assisted drug permeation via skin: Full-surface versus fractional ablation

Pharmaceutical Research

Volumn 31, Issue 2, 2014, Pages 382-393

  Lee, Woan Ruoh ^a,b   Shen, Shing Chuan ^a   Aljuffali, Ibrahim A ^c   Li, Yi Ching ^d   Fang, Jia You ^d,e,f  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

5 aminolevulinic acid; ablative laser; imiquimod; nanoparticle; vehicle

Indexed keywords

ALCOHOL; AMINOLEVULINIC ACID; IMIQUIMOD; MACROGOL 400; MYRISTIC ACID ISOPROPYL ESTER; NANOCARRIER; PROPYLENE GLYCOL; SOLID LIPID NANOPARTICLE;

ABLATION THERAPY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONFOCAL LASER MICROSCOPY; CONFOCAL MICROSCOPY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG HAIR LEVEL; DRUG PENETRATION; FEMALE; FRACTIONAL ABLATION; FULL SURFACE ABLATION; HAIR FOLLICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHILICITY; IN VITRO STUDY; IRRADIATION; LASER; LIPOPHILICITY; LOW LEVEL LASER THERAPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARTITION COEFFICIENT; PRIORITY JOURNAL; SKIN; SKIN PERMEABILITY; SKIN WATER LOSS; STEADY STATE; THERMODYNAMICS; ZETA POTENTIAL;

ADMINISTRATION, CUTANEOUS; AMINOLEVULINIC ACID; AMINOQUINOLINES; ANIMALS; DRUG DELIVERY SYSTEMS; FEMALE; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LASERS; MICE; MICE, INBRED ICR; MICE, NUDE; NANOPARTICLES; PERMEABILITY; PHARMACEUTICAL VEHICLES; POLYETHYLENE GLYCOLS; PROPYLENE GLYCOL; SKIN; SKIN ABSORPTION; WATER;

EID: 84896719572     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1167-4     Document Type: Article

References (38)

1. Lee WR, Shen SC, Fang CL, Zhuo RZ, Fang JY. Topical delivery of methotrexate via skin pretreated with physical enhancement techniques: low-fluence erbium:YAG laser and electroporation. Lasers Surg Med. 2008;40:468-76.
2. Lee WR, Shen SC, Al-Suwayeh SA, Yang HH, Li YC, Fang JY. Skin permeation of small-molecule drugs, macromolecules, and nanoparticles mediated by a fractional carbon dioxide laser: the role of hair follicles. Pharm Res. 2013;30:792-802.
3. Chen X, Shah D, Kositratna G, Manstein D, Anderson RR, Hædersdal M. Facilitation of transcutaneous drug delivery and vaccine immunization by a safe laser technology. J Control Release. 2012;159:43-51.
4. Lee WR, Shen SC, Pai MH, Yang HH, Yuan CY, Fang JY. Fractional laser as a tool to enhance the skin permeation of 5-aminolevulinic acid with minimal skin disruption: a comparison with conventional erbium:YAG laser. J Control Release. 2010;145:124-33.
5. Haak CS, Bhayana B, Farinelli WA, Anderson RR, Hædersdal M. The impact of treatment density and molecular weight for fractional laser-assisted drug delivery. J Control Release. 2012;163:335-41.
6. Ong MWS, Bashir SJ. Fractional laser resurfacing for acne scars: a review. Br J Dermatol. 2012;166:1160-9.
7. Lee WR, Shen SC, Al-Suwayeh SA, Yang HH, Yuan CY, Fang JY. Laser-assisted topical drug delivery by using a low-fluence fractional laser: imiquimod and macromolecules. J Control Release. 2011;153:240-8.
8. Metcalf S, Crowson AN, Naylor M, Haque R, Cornelison R. Imiquimod as an antiaging agent. J Am Acad Dermatol. 2007;56:422-5.
9. Salasche S, Shumack S. A review of imiquimod 5% cream for the treatment of various dermatological conditions. Clin Exp Dermatol. 2003;28:1-3.
10. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006;126:1251-5.
11. Musiol R, Serda M, Polanski J. Prodrugs in photodynamic anticancer therapy. Curr Pharm Des. 2011;17:3548-59.
12. Lin YK, Al-Suwayeh SA, Leu YL, Shen FM, Fang JY. Squalene-containing nanostructured lipid carriers promote percutaneous absorption and hair follicle targeting of diphencyprone for treating alopecia areata. Pharm Res. 2013;30:435-46.
13. Lanke SSS, Kolli CS, Strom JG, Banga AK. Enhanced transdermal delivery of low molecular weight heparin by barrier perturbation. Int J Pharm. 2009;365:26-33.
14. Teichmann A, Jacobi U, Ossadnik M, Richter H, Koch S, Sterry W, et al. Differential stripping: determination of the amount of topically applied substances penetrated into the hair follicles. J Invest Dermatol. 2005;125:264-9.
15. Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62:582-90.
16. Lee WR, Shen SC, Al-Suwayeh SA, Li YC, Fang JY. Erbium:YAG laser resurfacing increases skin permeability and the risk of excessive absorption of antibiotics and sunscreens: the influence of skin recovery on drug absorption. Toxicol Lett. 2012;211:150-8.
17. Menon GK, Kollias N, Doukas AG. Ultrastructural evidence of stratum corneum permeabilization induced by photomechanical waves. J Invest Dermatol. 2003;121:104-9.
18. Liu C, Zhang J, Yue Y, Luo Q, Zhu D. 1064 nm-Nd:YAG lasers with different output modes enhancing transdermal delivery: physical and physiological mechanisms. J Biomed Opt. 2013;18:061228.
19. El-Domyati M, Abd-El-Raheem T, Abdel-Wahab H, Medhat W, Hosam W, El-Fakahany H, et al. Fractional versus ablative erbium-yttrium-aluminum-garnet laser resurfacing for facial rejuvenation: an objective evaluation. J Am Acad Dermatol. 2013;68:103-12.
20. Bachhav YG, Heinrich A, Kalia YN. Using laser microporation to improve transdermal delivery of diclofenac: increasing bioavailability and the range of therapeutic applications. Eur J Pharm Biopharm. 2011;78:408-14.
21. Schön MP, Schön M. Imiquimod: mode of action. Br J Dermatol. 2007;157 Suppl 2:8-13.
22. Chollet JL, Jozwiakowski MJ, Phares KR, Reiter MJ, Roddy PJ, Schultz HJ, et al. Development of a topically active imiquimod formulation. Pharm Develop Technol. 1999;4:35-43.
23. Ramineni SK, Cunningham LL, Dziubla TD, Puleo DA. Development of imiquimod-loaded mucoadhesive films for oral dysplasia. J Pharm Sci. 2013;102:593-603.
24. Donnelly RF, McCarron PA, Zawislak AA, Woolfson AD. Design and physicochemical characterization of a bioadhesive patch for dose-controlled topical delivery of imiquimod. Int J Pharm. 2006;307:318-25.
25. Watkinson RM, Guy RH, Oliveira G, Hadgraft J, Lane ME. Optimisation of cosolvent concentration for topical drug delivery III-Influence of lipophilic vehicles on ibuprofen permeation. Skin Pharmacol Physiol. 2011;24:22-6.
26. Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH. Effect of propylene glycol on ibuprofen absorption into human skin in vivo. J Pharm Sci. 2008;97:185-97.
27. Panchagnula R, Salve PS, Thomas NS, Jain AK, Ramarao P. Transdermal delivery of naloxone: effect of water, propylene glycol, ethanol and their binary combinations on permeation through rat skin. Int J Pharm. 2001;219:95-105.
28. Watkinson RM, Guy RH, Hadgraft J, Lane ME. Optimisation of cosolvent concentration for topical drug delivery-II: influence of propylene glycol on ibuprofen permeation. Skin Pharmacol Physiol. 2009;22:225-30.
29. Garzon LC, Martinez F. Temperature dependence of solubility for ibuprofen in some organic and aqueous solvents. J Sol Chem. 2004;33:1379-95.
30. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70:633-40.
31. Schäfer-Korting M, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev. 2007;59:427-43.
32. Frum Y, Bonner MC, Eccleston GM, Meidan VM. The influence of drug partition coefficient on follicular penetration: in vitro human skin studies. Eur J Pharm Sci. 2007;30:280-7.
33. Lee WR, Shen SC, Liu CJ, Fang CL, Hu CH, Fang JY. Erbium:YAG laser-mediated oligonucleotide and DNA delivery via the skin: an animal study. J Control Release. 2006;115:344-53.
34. Zhang LW, Monteiro-Riviere NA. Use of confocal microscopy for nanoparticle drug delivery through skin. J Biomed Opt. 2013;18:061214.
35. Lopez RFV, Lange N, Guy RH, Bentley MVLB. Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev. 2004;56:77-94.
36. Araújo LMPC, Thomazine JA, Lopez RFV. Development of microemulsions to topically deliver 5-aminolevulinic acid in photodynamic therapy. Eur J Pharm Biopharm. 2010;75:48-55.
37. Casas A, Fukuda H, Di Venosa G, Batlle A. The influence of the vehicle on the synthesis of porphylins after topical application of 5-aminolaevulinic acid. Implications in cutaneous photodynamic sensitization. Br J Dermatol. 2000;143:564-72.
38. Valenta C, Auner BG, Loibl I. Skin permeation and stability studies of 5-aminolevulinic acid in a new gel and patch preparation. J Control Release. 2005;107:495-501.